Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.

BACKGROUND AND PURPOSE To compare the linear-quadratic (LQ) and the LQ-L formalism (linear cell survival curve beyond a threshold dose dT) for modeling local tumor control probability (TCP) in stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC). MATERIALS AND METHODS This study is based on 395 patients from 13 German and Austrian centers treated with SBRT for stage I NSCLC. The median number of SBRT fractions was 3 (range 1-8) and median single fraction dose was 12.5 Gy (2.9-33 Gy); dose was prescribed to the median 65% PTV encompassing isodose (60-100%). Assuming an α/β-value of 10 Gy, we modeled TCP as a sigmoid-shaped function of the biologically effective dose (BED). Models were compared using maximum likelihood ratio tests as well as Bayes factors (BFs). RESULTS There was strong evidence for a dose-response relationship in the total patient cohort (BFs>20), which was lacking in single-fraction SBRT (BFs<3). Using the PTV encompassing dose or maximum (isocentric) dose, our data indicated a LQ-L transition dose (dT) at 11 Gy (68% CI 8-14 Gy) or 22 Gy (14-42 Gy), respectively. However, the fit of the LQ-L models was not significantly better than a fit without the dT parameter (p=0.07, BF=2.1 and p=0.86, BF=0.8, respectively). Generally, isocentric doses resulted in much better dose-response relationships than PTV encompassing doses (BFs>20). CONCLUSION Our data suggest accurate modeling of local tumor control in fractionated SBRT for stage I NSCLC with the traditional LQ formalism.

[1]  T. Krieger,et al.  Four-dimensional treatment planning for stereotactic body radiotherapy. , 2007, International journal of radiation oncology, biology, physics.

[2]  P Okunieff,et al.  Radiation dose-response of human tumors. , 1995, International journal of radiation oncology, biology, physics.

[3]  Joachim Widder,et al.  Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study , 2009, Radiation oncology.

[4]  Aaron Ward,et al.  Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  Philippe Lambin,et al.  Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[6]  Thomas Krieger,et al.  Influence of calculation model on dose distribution in stereotactic radiotherapy for pulmonary targets. , 2005, International journal of radiation oncology, biology, physics.

[7]  Lech Papiez,et al.  Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study. , 2005, International journal of radiation oncology, biology, physics.

[8]  Y. Shibamoto,et al.  Radiobiological evaluation of the radiation dose as used in high-precision radiotherapy: effect of prolonged delivery time and applicability of the linear-quadratic model. , 2012, Journal of radiation research.

[9]  Y. Shibamoto,et al.  Estimation of errors associated with use of linear-quadratic formalism for evaluation of biologic equivalence between single and hypofractionated radiation doses: an in vitro study. , 2009, International journal of radiation oncology, biology, physics.

[10]  Matthias Guckenberger,et al.  Dose-response relationship for image-guided stereotactic body radiotherapy of pulmonary tumors: relevance of 4D dose calculation. , 2009, International journal of radiation oncology, biology, physics.

[11]  J. Sonke,et al.  Radiation pneumonitis after hypofractionated radiotherapy: evaluation of the LQ(L) model and different dose parameters. , 2010, International journal of radiation oncology, biology, physics.

[12]  Jan-Jakob Sonke,et al.  Modeling local control after hypofractionated stereotactic body radiation therapy for stage I non-small cell lung cancer: a report from the elekta collaborative lung research group. , 2012, International journal of radiation oncology, biology, physics.

[13]  Angelika Hoess,et al.  Stereotactic single‐dose radiotherapy (radiosurgery) of early stage nonsmall‐cell lung cancer (NSCLC) , 2007, Cancer.

[14]  X Allen Li,et al.  Extending the linear-quadratic model for large fraction doses pertinent to stereotactic radiotherapy. , 2004, Physics in medicine and biology.

[15]  F. Sterzing,et al.  Safety and Efficacy of Stereotactic Body Radiotherapy for Stage I Non–Small-Cell Lung Cancer in Routine Clinical Practice: A Patterns-of-Care and Outcome Analysis , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  P. Parikh,et al.  Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer. , 2011, International journal of radiation oncology, biology, physics.

[17]  David J Brenner,et al.  The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. , 2008, Seminars in radiation oncology.

[18]  Zhibin Huang,et al.  A Generalized Linear-Quadratic Model for Radiosurgery, Stereotactic Body Radiation Therapy, and High–Dose Rate Brachytherapy , 2010, Science Translational Medicine.

[19]  Y. Shibamoto,et al.  Compatibility of the linear-quadratic formalism and biologically effective dose concept to high-dose-per-fraction irradiation in a murine tumor. , 2011, International journal of radiation oncology, biology, physics.

[20]  Y. Onodera,et al.  Steep dose-response relationship for stage I non-small-cell lung cancer using hypofractionated high-dose irradiation by real-time tumor-tracking radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[21]  W. Mühlnickel,et al.  Stereotactic, high single-dose irradiation of stage I non-small cell lung cancer (NSCLC) using four-dimensional CT scans for treatment planning. , 2008, Lung cancer.

[22]  Jan Nyman,et al.  NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction , 2011, Acta oncologica.

[23]  Suresh Senan,et al.  Outcomes of stereotactic ablative radiotherapy for central lung tumours: a systematic review. , 2013, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  Wei Huang,et al.  Which is the optimal biologically effective dose of stereotactic body radiotherapy for Stage I non-small-cell lung cancer? A meta-analysis. , 2011, International journal of radiation oncology, biology, physics.

[25]  M. Astrahan,et al.  Some implications of linear-quadratic-linear radiation dose-response with regard to hypofractionation. , 2008, Medical physics.

[26]  David J. C. MacKay,et al.  Information Theory, Inference, and Learning Algorithms , 2004, IEEE Transactions on Information Theory.

[27]  Andrea Bezjak,et al.  Stereotactic body radiation therapy for inoperable early stage lung cancer. , 2010, JAMA.

[28]  J. Fowler The linear-quadratic formula and progress in fractionated radiotherapy. , 1989, The British journal of radiology.

[29]  Alfons G H Kessels,et al.  Comparison of the effectiveness of radiotherapy with photons, protons and carbon-ions for non-small cell lung cancer: a meta-analysis. , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[30]  S. Ahmad,et al.  Fitting techniques of cell survival curves in high-dose region for use in stereotactic body radiation therapy , 2009, Physics in medicine and biology.

[31]  Kurt Baier,et al.  Dose-response in stereotactic irradiation of lung tumors. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[32]  R. Kass Bayes Factors in Practice , 1993 .

[33]  Lech Papiez,et al.  Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. , 2008, International journal of radiation oncology, biology, physics.

[34]  Quynh-Thu Le,et al.  Results of a Phase I Dose-Escalation Study Using Single-Fraction Stereotactic Radiotherapy for Lung Tumors , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  T. Araki,et al.  Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma , 2004, Cancer.